Healthcare / Diagnostics & ResearchUpdated 2026-05-10 22:07 UTC

TMO stock hub

TMO trades against a final fair-value range of $384.14-$618.78, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

Read full analysis Valuation Archive

Fair value midpoint

$501

$384 - $619

Upside to midpoint

+5.6%

Based on latest report

Confidence

88/100

Data quality and model convergence

Market cap

$176.3B

NYSE

Our take

Research highlights

What our analysis says

Pulled from the latest published report. The full reasoning lives under /analysis.

Biggest opportunity

Bull case

Bull: A rapid thaw in biopharma funding reignites explosive demand for bioproduction and clinical research. Unmatched scale allows TMO to capture outsized market share while driving unprecedented margin expansion.

Biggest risk

Prolonged Biopharma Funding Winter

12-24 months

Recommended action

Hold

TMO is rated Hold at $474.46 versus the reconciled fair value midpoint of $500.89, implying +5.57% upside/downside. Confidence is separately disclosed at 88/100.

Market data

Live price

Current market quote for this ticker.

Current price

TMO

In the news

Latest news · TMO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Analysis map

Jump into the research surface

These links all point into /analysis/*, so a hub rollback leaves the report reader and legacy redirects live.

Forecast

Targets

Bull, base, and bear cases with expected-return framing.

Valuation

Models

Fair-value bridge, DCF, owner earnings, and peer multiples.

Sensitivity

Grid

Cost-of-equity and terminal-growth stress table.

Risks

Bear case

Kill scenarios, soft-pass flags, and downside catalysts.

Earnings

Decision tree

Next earnings setup and beat / inline / miss thresholds.

Position sizing

Checkpoints

Entry, exit, conviction, and quarterly monitoring rules.

Financials

History

Revenue, margins, cash flow, and balance-sheet context.

Peers

Comps

Relative valuation and profitability against the cohort.

Moat

Durability

Economic-profit evidence and competitive advantage risk.

Industry cycle

Context

Sector phase, capital cycle, and secular tailwinds.

Scorecard

Factors

Six-factor overlay and 9-category weighted scorecard.

Recommendation

Verdict

Final action, action steps, opportunity, and biggest risk.

Perspectives

Lenses

Growth, value, and income investor reads.

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E17.3

P25 12.6P50 18.3P75 33.7

Trailing P/E0

P25 15P50 23.3P75 38.5

ROE13.5

P25 -106.6P50 -46.9P75 -3.1

ROIC9

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Our take

Indicator catalog

All TMO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

285

Groups with data

Currency

USD

Showing 285 of 285 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000097745
Company name	Thermo Fisher Scientific Inc.
Country	United States
Country code	US
Cusip	883556102
Employees	125,000
Employees Change	3,000%
Employees Change Percent	2.46
Enterprise value	$212.7B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Diagnostics & Research
Isin	US8835561023
Last refreshed	2026-05-10
Market cap	$172.8B
Market cap category	Large-Cap
Price	$465
Price currency	USD
Rev Per Employee	361,576x
Sector	Healthcare
Sic	3829
Symbol	TMO
Website	https://www.thermofisher.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.96%
EV Earnings	31.06x
EV Sales Forward	4.37x
EV/EBIT	25.06x
EV/EBITDA	18.83x
EV/FCF	31.52x
EV/Sales	4.71x
FCF yield	3.91%
Forward P/E	18.28x
P/B ratio	3.33x
P/E ratio	25.56x
P/S ratio	3.82x
PE Ratio10 Y	31.53x
PE Ratio3 Y	31.69x
PE Ratio5 Y	30.99x
PEG ratio	2.12x
PS Forward	3.55x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	18.78%
EBITDA Margin	24.99%
FCF margin	14.93%
Gross margin	40.93%
Gross Profit	$18.5B
Gross Profit Growth	4.08%
Gross Profit Growth Q	4.66%
Gross Profit Growth3 Y	1.51%
Gross Profit Growth5 Y	0.02%
Net Income	$6.8B
Net Income Growth	5.13%
Net Income Growth Q	9.56%
Net Income Growth Quarters	2%
Net Income Growth Years	2%
Net Income Growth3 Y	4.37%
Net Income Growth5 Y	-2.88%
Pretax Margin	16.35%
Profit Margin	15.15%
Profit Per Employee	$54,784
Profitable Years	24
ROA	5
Roa5y	5.62
ROCE	8.6
ROE	13.52
Roe5y	15.21
ROIC	8.95
Roic5y	10.84

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	12.53%
Cagr15y	15.01%
Cagr1y	14.44%
Cagr20y	13.44%
Cagr3y	-4.94%
Cagr5y	0.12%
Div CAGR10	11.36%
Div CAGR3	12.08%
Div CAGR5	13.85%
EPS Growth	6.67
EPS Growth Q	11.31
EPS Growth Quarters	6
EPS Growth Years	2
EPS Growth3 Y	5.84
EPS Growth5 Y	-1.75
FCF Growth	0.36%
FCF Growth Q	126.04%
FCF Growth3 Y	6.29%
FCF Growth5 Y	-3.5%
OCF Growth	1.82%
OCF Growth Q	64.87%
OCF Growth10 Y	10.43%
OCF Growth3 Y	2.56%
OCF Growth5 Y	-3.52%
Revenue Growth	5.36x
Revenue Growth Q	6.19x
Revenue Growth Quarters	7x
Revenue Growth Years	2x
Revenue Growth3 Y	1.05x
Revenue Growth5 Y	4.72x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.43
Assets	$113.3B
Cash	$3.3B
Current Assets	$22.3B
Current Liabilities	$14.6B
Debt	$43.2B
Debt EBITDA	$3.66
Debt Equity	$0.83
Debt FCF	$6.4
Equity	$52.1B
Interest Coverage	5.77
Liabilities	$61.2B
Long Term Assets	$91B
Long Term Liabilities	$46.6B
Net Cash	$-39.9B
Net Cash By Market Cap	$-23.09
Net Debt EBITDA	$3.53
Net Debt Equity	$0.77
Net Debt FCF	$5.91
Tangible Book Value	$-22.4B
Tangible Book Value Per Share	$-60.27
WACC	7.92

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.53
Inventory Turnover	4.98
Net Working Capital	$7.5B
Quick ratio	0.97
Working Capital	$7.7B
Working Capital Turnover	$5.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.38%
Dividend Growth	10%
Dividend Growth Years	8%
Dividend per share	$1.88
Dividend Years	15
Dividend Yield	0.4%
Ex Div Date	2026-03-13
Last Dividend	$0.47
Payout Frequency	Quarterly
Payout Ratio	9.67%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	225.56%
1Y total return	14.43%
200-day SMA	527.8
3Y total return	-14.1%
50-day SMA	490.7
50-day SMA vs 200-day SMA	50under200
5Y total return	0.62%
All Time High	672.3
All Time High Change	-30.84%
All Time High Date	2021-12-31
All Time Low	1
All Time Low Change	46,465.19%
All Time Low Date	1982-08-11
ATR	15.16
Beta	0.88
Beta1y	1.04
Beta2y	0.7
Ch YTD	-19.75
High	473.5
High52	644
High52 Date	2026-01-22
High52ch	-27.79%
Low	456.4
Low52	385.5
Low52 Date	2025-06-18
Low52ch	20.64%
Ma50ch	-5.25%
Premarket Change Percent	-0.07
Premarket Price	$474
Premarket Volume	1,008
Price vs 200-day SMA	-11.89%
RSI	40.07
RSI Monthly	43.05
RSI Weekly	39.57
Sharpe ratio	0.46x
Sortino ratio	0.9
Total Return	1.78%
Tr YTD	-19.67
Tr15y	714.28%
Tr1m	-5.01%
Tr1w	-0.9%
Tr3m	-14.25%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	18
Analyst Count Top	1
Analyst Price Target Top	$600
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$5.23
Earnings EPS Estimate Growth	1.55
Earnings Revenue Estimate	10,854,979,360x
Earnings Revenue Estimate Growth	4.74x
Operating Income	$8.5B
Operating Income Growth	8.22
Operating Income Growth Q	7.01
Operating Income Growth3 Y	4.42
Operating Income Growth5 Y	-3.25
Operating margin	18.78
Price target	$632
Price Target Change	$36.02
Price Target Change Top	$29.03

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	370,687,718%
Float Percent	99.75%
Net Borrowing	7,560,000,000
Shares Insiders	0.13%
Shares Institutions	93.63%
Shares Out	371,621,465
Shares Qo Q	-1.06%
Shares Yo Y	-1.38%
Short Float	1.22%
Short Ratio	2.38
Short Shares	1.22

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$6.4B
Average Volume	2,244,944.85x
Bv Per Share	139.7
CAPEX	$-1.5B
Ch10y	216.4
Ch15y	670.4
Ch1m	-5.01
Ch1w	-0.9
Ch1y	14.01
Ch20y	1,078.7
Ch3m	-14.34
Ch3y	-14.89
Ch5y	-0.74
Ch6m	-18.76
Change	-1.99%
Change From Open	-1.79
Close	474.5
Days Gap	-0.2
Depreciation Amortization	2,809,000,000
Dollar Volume	1,816,182,120
Earnings Date	2026-04-23
Earnings Time	bmo
EBIT	$8.5B
EBITDA	$11.3B
EPS	$18.19
F Score	4
FCF	$6.7B
FCF EV Yield	3.17x
FCF Per Share	$18.16
Financing CF	2,996,000,000
Fiscal Year End	December
Founded	1,956
Goodwill	55,187,000,000
Graham Number	239.17716
Graham Upside	-48.56
Income Tax	$522M
Investing CF	-12,481,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-23
Last Report Date	2026-03-28
Last Split Date	1996-06-06
Last Split Type	Forward
Last10k Filing Date	2026-02-26
Lynch Fair Value	$90.97
Lynch Upside	-80.44
Ma150	543.4
Ma150ch	-14.43%
Ma20	490.6
Ma20ch	-5.21%
Net CF	-892,000,000
Next Earnings Date	2026-07-22
Open	473.5
Optionable	Yes
P FCF Ratio	25.61
P OCF Ratio	20.85
Payment Date	2026-04-15
Position In Range	50.44
Post Close	465
Postmarket Change Percent	-0.11
Postmarket Price	$465
Ppne	10,658,000,000
Pre Close	474.5
Price Date	2026-05-08
Price EBITDA	$15.3
Relative Volume	1.74x
Revenue	45,197,000,000x
SBC By Revenue	0.7x
Share Based Comp	318,000,000
Tax By Revenue	1.15x
Tax Rate	7.07%
Tr20y	1,145.88%
Tr6m	-18.62%
Us State	Massachusetts
Views	70
Volume	3,905,768
Z Score	3.31

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

9/10

Business quality stays separate from stock attractiveness.

Forward P/E

17.3x

Valuation uses the full report model stack, not a single multiple.

Next action

Hold

Final action steps are kept in the recommendation tab.

Our take

Income

TMO dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.4%

$1.88 annual per share

Payout ratio

+9.7%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+13.9%

8 consecutive years of growth

Total shareholder yield

+1.8%

Next ex-dividend date: 2026-03-13

Performance

TMO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TMO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+93.6%

Float: +99.7% of shares outstanding

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

TMO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

40.1

Neutral momentum band

Price vs 200-day MA

-11.9%

50/200-day relationship not available

Beta (5Y)

0.88

Moves roughly with the market

Sharpe ratio

0.46

Risk-adjusted return — higher is better; >1.0 is solid.

Peers

TMO vs. sector cohort

Currency-neutral comparison: P/E, P/S, ROIC, 5Y revenue CAGR, and 1Y total return. Market-cap column appears only when every peer reports in the same currency.

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	4.3T	35.6x	9.5x	104.3%	+6.8%	+50.1%	Vender
ABNB	Airbnb Inc.	84B	34.7x	6.6x	15.9%	+29.9%	+14.9%	Manter
ADBE	Adobe Inc.	102.3B	14.8x	4.2x	63.3%	+12.3%	-34.3%	Compra forte

Questions

About TMO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TMO stock rating?

Thermo Fisher Scientific Inc. is currently shown with Hold in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TMO analysis?

The full report lives at /stocks/TMO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TMO?

The latest report frames TMO around $384 to $619. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TMO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.